Product Information

IMATINIB MESYLATE 400 MG TAB is a generic product labeled by Dr. Reddy's Laboratories Inc., priced at $2.8764 per EA under NDC 43598034531. Its NADAC has been published 306 times since Oct 14, 2020.

FDA first approved this application on Aug 13, 2018. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.

IMATINIB MESYLATE 400 MG TAB

Imatinib
$2.8764per EA

Strength

400 mg/1

NDC

43598034531

Classification

Generic

Dosage Form

TABLET

Route

ORAL

Effective Date

8/19/2026

Active Ingredients

IMATINIB MESYLATE

Approval Type

Generic (ANDA)

FDA Application

ANDA206547

FDA Approved

8/13/2018

TE Code

AB

On Market Since

8/13/2018

Pharmacological Classes

Bcr-Abl Tyrosine Kinase Inhibitors
Cytochrome P450 2D6 Inhibitors
Cytochrome P450 3A4 Inhibitors
Kinase Inhibitor

Price Statistics

The NADAC for IMATINIB MESYLATE 400 MG TAB has been published 306 times since Oct 14, 2020, and over the history we have for it it has declined 67.7%. The table below summarizes its recorded NADAC range and movement.

Current price$2.8764 per EA
All-time high$8.9088 (Oct 14, 2020)
All-time low$1.4080 (Aug 23, 2023)
52-week high$3.2150
52-week low$2.8764
Median price$2.6946
Average price$2.9590
Largest weekly change-36.2% (Jul 21, 2021)
Weeks tracked306
Tracking sinceOct 14, 2020

Price History

1W

-0.9%

1M

-0.9%

3M

-4.7%

6M

-10.5%

1Y

-5.4%

3Y

+75.8%

5Y

-25.6%

All

-67.7%

Generic Alternatives

The matcher finds 1 manufacturer offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 4% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.

Lowest-Cost Alternatives

Save up to 4%

1 alternative • Same active ingredient

Frequently asked questions

What is the NADAC price of IMATINIB MESYLATE 400 MG TAB?

The current National Average Drug Acquisition Cost (NADAC) for IMATINIB MESYLATE 400 MG TAB, manufactured by Dr. Reddy's Laboratories Inc., is $2.8764 per EA (NDC 43598034531), effective Aug 19, 2026.

How has the price of IMATINIB MESYLATE 400 MG TAB changed over time?

Over the history we have for it, the NADAC for IMATINIB MESYLATE 400 MG TAB has declined 67.7%. It has been tracked across 306 weekly CMS publications since Oct 14, 2020.

What are the highest and lowest recorded NADAC prices for IMATINIB MESYLATE 400 MG TAB?

Since Oct 14, 2020, the NADAC for IMATINIB MESYLATE 400 MG TAB has ranged from a low of $1.4080 (Aug 23, 2023) to a high of $8.9088 (Oct 14, 2020), with a median of $2.6946 per EA.

Are there cheaper alternatives to IMATINIB MESYLATE 400 MG TAB?

Yes. 1 manufacturer publishes a NADAC-priced product with the same active ingredient and strength in a comparable dosage form. The lowest-priced option, IMATINIB MESYLATE 400 MG TAB, is $2.7670 per EA — about 4% below IMATINIB MESYLATE 400 MG TAB.

Who manufactures IMATINIB MESYLATE 400 MG TAB?

IMATINIB MESYLATE 400 MG TAB (NDC 43598034531) is labeled by Dr. Reddy's Laboratories Inc., and CMS classifies it as a generic product.